- Home
- MRSN
as 03-28-2025 4:00pm EST
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 71.9M | IPO Year: | 2017 |
| Target Price: | $4.00 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.37 - $4.64 | Next Earning Date: | 03-03-2025 |
| Revenue: | $40,497,000 | Revenue Growth: | 9.88% |
| Revenue Growth (this year): | -38.06% | Revenue Growth (next year): | 67.68% |
Stock Insider Trading Activity of Mersana Therapeutics Inc. (MRSN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Protopapas Anna | MRSN | Director | Jan 15 '25 | Sell | $0.58 | 8,637 | $5,009.46 | 168,041 | |
| Lowinger Timothy B | MRSN | SVP, Chief Sci.&Tech. Officer | Jan 15 '25 | Sell | $0.58 | 8,048 | $4,667.84 | 257,673 | |
| Bala Mohan | MRSN | SVP, Chief Development Officer | Jan 15 '25 | Sell | $0.58 | 5,939 | $3,444.62 | 68,872 | |
| Mandelia Ashish | MRSN | VP, Chief Accounting Officer | Jan 15 '25 | Sell | $0.58 | 3,554 | $2,061.32 | 57,519 | |
| Huber Martin H. Jr. | MRSN | President, CEO | Jan 15 '25 | Sell | $0.58 | 4,514 | $2,618.12 | 122,875 | |
| Carvajal Alejandra | MRSN | SVP, Chief Legal Officer | Jan 15 '25 | Sell | $0.58 | 5,096 | $2,955.68 | 78,296 | |
| DeSchuytner Brian | MRSN | SVP, COO & CFO | Jan 15 '25 | Sell | $0.58 | 8,470 | $4,912.60 | 121,393 | |
| Protopapas Anna | MRSN | Director | Jan 14 '25 | Sell | $0.63 | 6,191 | $3,900.33 | 168,041 | |
| Lowinger Timothy B | MRSN | SVP, Chief Sci.&Tech. Officer | Jan 14 '25 | Sell | $0.63 | 1,794 | $1,130.22 | 257,673 | |
| Mandelia Ashish | MRSN | VP, Chief Accounting Officer | Jan 14 '25 | Sell | $0.63 | 1,791 | $1,128.33 | 57,519 |
Latest Mersana Therapeutics Inc. News
MRSN Breaking Stock News: Dive into MRSN Ticker-Specific Updates for Smart Investing
Simply Wall St.
23 days ago
Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates
Simply Wall St.
24 days ago
Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts
Simply Wall St.
25 days ago
Mersana Therapeutics Full Year 2024 Earnings: Beats Expectations
GuruFocus.com
25 days ago
Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ...
Thomson Reuters StreetEvents
25 days ago
Q4 2024 Mersana Therapeutics Inc Earnings Call
Zacks
a month ago
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results
GuruFocus.com
a month ago
What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings
Compare MRSN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRSN Mersana Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.